Moderna plots vaccines against 15 pathogens with future pandemic potential | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Wednesday
July 23, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
WEDNESDAY, JULY 23, 2025
Moderna plots vaccines against 15 pathogens with future pandemic potential

Coronavirus chronicle

Reuters
08 March, 2022, 11:05 am
Last modified: 08 March, 2022, 11:13 am

Related News

  • Moderna ties up with Immatics to boost cancer vaccine development
  • Moderna says updated Covid vaccine is effective against newer variant
  • Cancer and heart disease vaccines expected to be ready by 2030
  • Moderna reports positive results for RSV vaccine
  • Moderna refused China request to reveal vaccine technology: Financial Times

Moderna plots vaccines against 15 pathogens with future pandemic potential

Reuters
08 March, 2022, 11:05 am
Last modified: 08 March, 2022, 11:13 am
Moderna has recently signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world. Photo: Reuters
Moderna has recently signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world. Photo: Reuters

Moderna Inc said on Monday it plans to develop and begin testing vaccines targeting 15 of the world's most worrisome pathogens by 2025 and will permanently wave its Covid-19 vaccine patents for shots intended for certain low- and middle-income countries.

The US biotechnology company also said it will make its messenger RNA (mRNA) technology available to researchers working on new vaccines for emerging and neglected diseases through a program called mRNA Access.

Moderna announced its strategy ahead of the Global Pandemic Preparedness Summit sponsored by the UK government and the Coalition for Epidemic Preparedness Innovations (CEPI), an international coalition set up five years ago to prepare for future disease threats.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Moderna is already collaborating with partners on vaccines against some of the 15 pathogens, which include Chikungunya, Crimean-Congo hemorrhagic fever, Dengue, Ebola, Malaria, Marburg, Lassa fever, MERS and Covid-19.

Those collaborations include a Nipah virus vaccine with the US National Institutes of Health and an HIV vaccine with the Gates Foundation and the International AIDS Vaccine Initiative, Moderna President Stephen Hoge said in an interview.

The company will either seek out new partners for the others or develop them internally, he said.

Moderna Chief Executive Stephane Bancel told a virtual press briefing on Monday that the 15 viruses are known threats that have not been addressed by many large drugmakers. The Covid-19 pandemic, which has killed six million people worldwide and sickened millions more, has made clear that needs to change, Bancel said.

"Too many lives were lost in the last few years," he said.

Early in the Covid pandemic, Moderna pledged not to enforce its vaccine patents during the emergency phase of the health crisis.

That has allowed for development of a vaccine manufacturing plant in Africa backed by the World Health Organization as part of a pilot project to give poor and middle-income countries the know-how to make Covid-19 vaccines.

Moderna said it will make that pledge permanent for the 92 low- and middle income countries that qualify for assistance under the COVAX Advance Market Commitment (AMC) led by the GAVI vaccine alliance.

A company spokesperson said Moderna will not enforce patents for Covid-19 vaccines developed in South Africa by WHO-backed Afrigen Biologics for AMC-92 low- and middle-income countries.

Although it will not enforce its patents in these countries, Hoge said Moderna does not intend to share its vaccine technology with the WHO-backed technology transfer hub in South Africa, in spite of lobbying efforts by the organization.

Earlier on Monday, the company said it will set up a manufacturing facility in Kenya, its first in Africa, to produce mRNA vaccines, including against Covid-19.

As part of its future pandemic plan, Moderna intends to make its technology available to academic research labs to test their own theories for vaccines to address emerging and neglected diseases. Hoge said some of these may eventually result in partnerships with Moderna to address the 15 priority pathogens.

"What we want to make sure happens is that scientists who have great ideas for how they could make vaccines will be able to access our standards and technology, almost as if they worked at Moderna," Hoge said.

Initially, the program will start with a few academic labs, but Hoge expects it to expand rapidly. He sees the program as a way to expand discovery of vaccines using mRNA technology.

"We want to make sure that we allow others to explore the space that frankly, we can't get to," he said. "And that's really what this is about."

Top News

Moderna / Moderna Inc / Moderna Vaccine / pathogen

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: CA Press Wing
    Stronger stance needed on maintaining law and order: Political parties to CA
  • Photo: Syed Zakir Hossain/TBS
    Secretariat protest: 75 injured in police-protester clash over edu adviser's resignation for delaying HSC rescheduling
  • Bangladesh win nail-biter to clinch series win 
    Bangladesh win nail-biter to clinch series win 

MOST VIEWED

  • Training aircraft crashes at the Diabari campus of Milestone College on 21 July 2025. Photo: Courtesy
    BAF jet crash at Milestone school: At least 20 including children, pilot dead; 171 hospitalised
  • Flight Lieutenant Md Towkir Islam. Photo: Collected
    Pilot tried to avoid disaster by steering crashing jet away from populated area: ISPR
  • An idle luxury: Built at a cost of Tk450 crore, this rest house near Parki Beach in Anwara upazila has stood unused for six months. Perched on the southern bank of the Karnaphuli, the facility now awaits a private lease as the Bridge Division seeks to put it to use. Photo: Md Minhaz Uddin
    Karnaphuli Tunnel’s service area holds tourism promises, but tall order ahead
  • Bangladesh declares one-day state mourning following plane crash on school campus
    Bangladesh declares one-day state mourning following plane crash on school campus
  • 91-day treasury bills rate falls 1.13 percentage points to 10.45% in a week
    91-day treasury bills rate falls 1.13 percentage points to 10.45% in a week
  • Air Force F-7 BJI training aircraft crashes at Milestone College in Uttara
    Air Force F-7 BJI training aircraft crashes at Milestone College in Uttara

Related News

  • Moderna ties up with Immatics to boost cancer vaccine development
  • Moderna says updated Covid vaccine is effective against newer variant
  • Cancer and heart disease vaccines expected to be ready by 2030
  • Moderna reports positive results for RSV vaccine
  • Moderna refused China request to reveal vaccine technology: Financial Times

Features

Photo: Mehedi Hasan/TBS

Aggrieved nation left with questions as citizens rally to help at burn institute

7h | Panorama
Photo: TBS

Mourning turns into outrage as Milestone students seek truth and justice

2h | Panorama
Illustration: TBS

Uttara, Jatrabari, Savar and more: The killing fields that ran red with July martyrs’ blood

1d | Panorama
Despite all the adversities, girls from the hill districts are consistently pushing the boundaries to earn repute and make the nation proud. Photos: TBS

Ghagra: Where dreams rise from dust for Bangladesh women's football

2d | Panorama

More Videos from TBS

What information did the director of the NBPSI give about the admitted patients?

What information did the director of the NBPSI give about the admitted patients?

25m | TBS Today
What is discussed at the Chief Advisor's meeting?

What is discussed at the Chief Advisor's meeting?

40m | TBS Today
Two advisors and press secretary were blocked at Milestone for 8 hours

Two advisors and press secretary were blocked at Milestone for 8 hours

50m | TBS Today
Chief advisor's meeting with 4 parties; what was discussed?

Chief advisor's meeting with 4 parties; what was discussed?

1h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net